MORTALITY AMONG INDIVIDUALS PRESCRIBED OPIOID-AGONIST THERAPY IN SCOTLAND, 2011-2022: A NATIONAL RETROSPECTIVE COHORT STUDY

Authors:

<u>McAuley A</u>^{1,2}, Fraser R^{1,2}, Glancy M^{1,2}, Yeung A^{1,2}, Jones H E³, Vickerman P³, Fraser H³, Allen L^{3,2}, McDonald S A^{1,2}, Stone J³, Liddell D⁴, Barnsdale L¹, Priyadarshi S^{5,1}, Markoulidakis A^{3,2}, Hickman M³ and Hutchinson SJ^{1,2}

¹School of Health and Life Sciences, Research Centre for Health (ReacH), Glasgow Caledonian University, Cowcaddens Road, Glasgow, G4 0BA, UK, ²Public Health Scotland, Gyle Square, South Gyle Crescent, Edinburgh, EH12 9EB, UK, ³Bristol Medical School, University of Bristol, Tyndall Avenue, Bristol, BS8 1UD, UK, ⁴Scottish Drugs Forum, Mitchell St, Glasgow, G1 3LN, UK, ⁵Glasgow Alcohol and Drug Recovery Services, Glasgow, UK

Background:

Scotland's drug-related death (DRD) rate has increased rapidly to one of the highest in the world. Our aim was to examine the extent to which opioid-agonist therapy (OAT) in Scotland is protective against drug-related mortality and how this effect has varied over time.

Methods:

We included individuals in Scotland with opioid use disorder who received at least one OAT prescription between 1 January 2011 and 31 December 2022. We calculated drug-related mortality rates and used quasi-Poisson regression models to estimate trends over time and by OAT exposure, adjusting for potential confounding.

Results:

In a cohort of 49,435 individuals prescribed OAT with a total of 360,000 person years of follow-up, DRD rates more than trebled from 6·36 per 1,000 pys (95% CI: 5·73 to 7·01) in 2011-12 to 21.45 (95% CI: 20·31 to 22·63) in 2019-20. By 2021-22, there was evidence that this rapid rise had begun to plateau. DRD rates were around three and a half times higher (HR 3.62, 95% CI: 3.34 to 3.93) for those off OAT at time of death relative to those on OAT after adjustment for confounders. However, DRD risk increased over time after adjustment for both people off *and* on OAT.

Conclusion:

Drug-related mortality rates among people with opioid use disorders in Scotland increased between 2011 and 2020, before levelling off during the Covid-19 pandemic. OAT remains protective but is insufficient on its own to slow the increase in DRD risk experienced by people who are opioid dependent in Scotland.

Disclosure of Interest Statement:

All authors report no conflicts of interest relevant to this work.